Taipei, Taiwan

Chun-Chun Cheng


Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):

Title: The Innovations of Chun-Chun Cheng

Introduction

Chun-Chun Cheng is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer detection and treatment through his innovative work on antibodies. His research focuses on the development of anti-EGF like domain multiple 6 (EGFL6) antibodies, which have the potential to revolutionize cancer diagnostics and therapies.

Latest Patents

Cheng holds a patent for the invention titled "Anti-EGF like domain multiple 6 (EGFL6) antibodies." This invention relates to the creation of anti-EGFL6 antibodies, particularly single-chain antibody fragments (scFv) and humanized antibodies. These antibodies are designed to bind to EGFL6, inhibiting angiogenesis and cancer cell growth. This groundbreaking work has the potential to enhance cancer detection and treatment methodologies.

Career Highlights

Throughout his career, Chun-Chun Cheng has been associated with prestigious institutions such as Taipei Medical University and Changhua Christian Medical Foundation Changhua Christian Hospital. His work in these organizations has allowed him to collaborate with other experts in the field and contribute to significant advancements in medical research.

Collaborations

Cheng has worked alongside notable colleagues, including Yu-Ching Lee and Shiow-Lin Pan. Their collaborative efforts have furthered the understanding and application of anti-EGFL6 antibodies in cancer research.

Conclusion

Chun-Chun Cheng's innovative work in developing anti-EGFL6 antibodies marks a significant advancement in cancer detection and treatment. His contributions to the field highlight the importance of research and collaboration in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…